menu
    • menu
    [{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Dehydrated human amniotic membrane allograft","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Technologies \/ Not Applicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dehydrated Human Amniotic Membrane","moa":"IL-1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Technologies \/ Not Applicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Dehydrated Human Amniotic Membrane","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Technologies \/ Not Applicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"NovaBay Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Amniotic Tissue Allograft","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ NovaBay Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Technologies \/ NovaBay Pharmaceuticals"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Private Placement","leadProduct":"Amniotic Tissue Allograft","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Technologies \/ Undisclosed"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Amniotic Tissue Allograft","moa":"","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Not Applicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Amniotic Chorion Tissue Allograft","moa":"","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Not Applicable"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Kane Biotech","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"","graph1":"Podiatry","graph2":"Approved","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ BioStem Technologies","highestDevelopmentStatusID":"12","companyTruncated":"BioStem Technologies \/ BioStem Technologies"},{"orgOrder":0,"company":"BioStem Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Amniotic Tissue Allograft","moa":"","graph1":"Podiatry","graph2":"Phase I","graph3":"BioStem Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"BioStem Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioStem Technologies \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BioStem Technologies

    Menu

    BioStem Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioStem Launches Trial for BioREtain® Technology in Diabetic Foot Ulcers

                            Details : Vendaje is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                            Product Name : Vendaje

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            January 08, 2025

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Study Phase : Approved

                            Recipient : Kane Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kane Biotech Changes US Partner for Revyve™ Antimicrobial Wound Gel Distribution

                            Details : BioStem Technologies will acquire exclusive US distribution rights for revyve from ProgenaCare Global.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 27, 2024

                            Lead Product(s) : Polyhexanide,Edetate Calcium Disodium,Citric Acid

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved

                            Recipient : Kane Biotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Chorion Tissue Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioStem Begins Trial for BioREtain® in Diabetic Foot Ulcers

                            Details : BR-AC is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                            Product Name : BR-AC

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 02, 2024

                            Lead Product(s) : Amniotic Chorion Tissue Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioStem Receives IRB Approval to Study Vendaje® for Diabetic Foot Ulcers

                            Details : Vendaje is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                            Product Name : Vendaje

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 21, 2024

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Undisclosed

                            Deal Size : $2.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            BioStem Technologies Closes Oversubscribed $2M Private Placement

                            Details : The proceeds will be used to complete clinical trials to support product performance, expand brand awareness and product distribution, including Vendaje Optic (amniotic tissue allograft), a structural tissue allograft composed of the amnion layer of the ...

                            Product Name : Vendaje Optic

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 03, 2023

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Undisclosed

                            Deal Size : $2.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : NovaBay Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allogra...

                            Details : Under the agreement, NovaBay has been granted the right to commercialize BioStem Technologies’ Vendaje Optic (amniotic tissue allograft) as Avenova® Allograft, which is intended for use as a protective covering during the repair of ocular surfaces.

                            Product Name : Vendaje Optic

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 11, 2023

                            Lead Product(s) : Amniotic Tissue Allograft

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : NovaBay Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dehydrated Human Amniotic Membrane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Center for Medicare Services Established National Pricing of Vendaje™ in All MAC regions

                            Details : VENDAJE is a structural tissue allograft composed of the dehydrated human amniotic membrane of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds.

                            Product Name : Vendaje

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : Dehydrated Human Amniotic Membrane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dehydrated Human Amniotic Membrane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue...

                            Details : The study investigates a standardized method to quantify the elution of growth factors and cytokines in BioStem’s dehydrated amniotic membrane (Vendaje®) and dehydrated amnion/chorion (Vendaje AC®) placental derived allografts as a function of surfac...

                            Product Name : Vendaje

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 13, 2022

                            Lead Product(s) : Dehydrated Human Amniotic Membrane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            BioStem Technologies

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dehydrated human amniotic membrane allograft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™

                            Details : The TRIP response indicated that VENDAJE™ does meet the criteria in 21 CFR 1271.10(a) for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271.

                            Product Name : Vendaje

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 25, 2021

                            Lead Product(s) : Dehydrated human amniotic membrane allograft

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth